FDA Clearance Tracker · P930014-S154
AcrySof Posterior Chamber Intraocular Lenses
Last checked: Nov 20, 2026Latest source record: Mar 21, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Mar 21, 2025
Approved
Time to decision
59 days
Received Jan 21, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P930014-S154
- Device name
- AcrySof Posterior Chamber Intraocular Lenses
- Applicant
- Alcon Laboratories, Inc.
- Applicant location
- Fort Worth, TX
- Received
- Jan 21, 2025
- Decided
- Mar 21, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P930014
Device type
- Device type
- intraocular lens (HQL)
- Device class
- Class III
- Regulation
- 21 CFR 886.3600
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
approval for a manufacturing site, PT. Ciba Vision Batam, located at Jalan Beringin Lot #204, Batamindo Industrial Park, Mukakuning, Batam Island 29433, Indonesia. This site will perform manufacturing and sterilization of the AcrySof single-piece intraocular lens - models SN60WF, SN60AT, SA60WF AND SA60AT
Source documents
Other decisions for Alcon Laboratories, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K254052 · Decided Feb 13, 2026 · 58 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.